1. Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154-63.
2. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443-50.
3. O’Sullivan JD, Lees AJ. Nonparkinsonian tremors. Clin Neuropharmacol. 2000;23(5):233-8.
4. Furukawa Y, Kish SJ. Dopa-responsive dystonia: recent advances and remaining issues to be addressed. Mov Disord. 1999;14(5):709-15.
5. Tissingh G, Bergmans P, Booij J, Winogrodzka A, Stoof JC, Wolters EC, et al. [123I]beta-CIT single-photon emission tomography in Parkinson’s disease reveals a smaller decline in dopamine transporter s with age than in controls. Eur J Nucl Med. 1997;24(9):1171-4.
6. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]-FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867-9.
7. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta- carbomethoxy-3beta- (4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med. 1998;39(7):1143–8.
8. Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med. 1998;39(11):1879–84.
9. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine- 123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med. 1998;39(9):1500–8.
10. Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging. 2011;38(4):764–73.
11. Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med. 2003;44(7):1184-93.
12. Pareto D, Cot A, Pavı´a J, Falcón C, Juvells I, Lomeña F, et al. Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging. Eur J Nucl Med Mol Imaging. 2003;30(10):1322–9.
13. Maebatake A, Sato M, Kagami R, Yamashita Y, Komiya I, Himuro K, et al. An anthropomorphic phantom study of brain dopamine transporter SPECT images obtained using different SPECT/ CT devices and collimators. J Nucl Med Technol. 2015;43(1):41-6.
14. Ishii K, Hanaoka K, Okada M, Kumano S, Komeya Y, Tsuchiya N, et al. Impact of CT attenuation correction by SPECT/CT in brain perfusion images. Ann Nucl Med. 2012;26(3):241-7.
15. Vija HA, Hawman EG, Engdahl JC. Analysis of a SPECT OSEM reconstruction method with 3D beam modeling and optional attenuation correction: phantom studies. IEEE Nucl Sci Symp Conf Record. 2003;4:2662-6.
16. Winz OH, Hellwig S, Mix M, Weber WA, Mottaghy FM, Schäfer WM, et al. Image quality and data quantification in dopamine transporter SPECT: advantage of 3-dimentional OSEM reconstruction? Clin Nucl Med. 2012;37(9):866-71.
17. Onishi H, Motomura N, Fujino K, Natsume T, Haramoto Y. Quantitative performance of advanced resolution recovery strategies on SPECT images: evaluation with use of digital phantom models. Radiol Phys Technol. 2013;6(1):42-53.
18. Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K, et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging. 2010;37(1):23-35.
19. He X, Frey EC, Links JM, Song X, Tsui BM. Comparison of penetration and scatter effects on defects on defect contrast for GE and Siemens LEHR collimators in myocardial perfusion SPECT a simulation study. IEEE Trans Nucl Sci. 2005;52(5):1359-64.
20. Bieńkiewicz M, Górska-Chrzastek M, Siennicki J, Gajos A, Bogucki A, Mochecka-Thoelke A, et al. Impact of CT based attenuation correction on quantitative assessment of DaTSCAN ((123)I-Ioflupane) imaging in diagnosis of extrapyramidal diseases. Nucl Med Rev Cent East Eur. 2008;11(2):53-8.
21. Lange C, Seese A, Schwarzenböck S, Steinhoff K, Umland-Seidler B, Krause BJ, et al. CT-based attenuation correction in I-123-ioflupane SPECT. PLoS ONE. 2014;9(9):e108328.